Clinical Trial Update: A Bioequivalence Study of SCH 530348 2.5 mg Tablets (P06558) [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study of SCH 530348 2.5 mg tablets (P06558) has completed, reported by Merck Sharp & Dohme LLC, for Acute Coronary Syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• SCH 530348 (SCH-530348)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Acute Coronary Syndrome | Phase 1 | Status: COMPLETED